At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 303 enrolled
Drug / intervention
Ixekizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
In Brief
A Phase 3 clinical trial evaluating Ixekizumab and Placebo for Axial Spondyloarthritis. Completed, enrolled 303 participants across 109 sites in 16 countries.
Detailed Summary
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as ixekizumab in biologic disease modifying antirheumatic drug (bDMARD) naïve participants with nonradiographic axial spondyloarthritis (nonrad-axSpA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAxial Spondyloarthritis
CountriesArgentina, Austria, Brazil, Canada, Czechia, Finland, Germany, Japan, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russia, South Korea, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2016
Enrollment StartAug 2016
Primary CompletionMar 2019
Study CompletionMay 2019
TodayJul 2026
First PostedMay 2, 2016
Enrollment StartAug 2, 2016
Primary CompletionMar 1, 2019
Study CompletionMay 7, 2019
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 10.2 years ago
Interventions
Ixekizumabdrug
Administered SC
Placebodrug
Administered SC